Guidelines for Deprescribing in Complex Multimorbidity: Evidence-Based Approaches and Clinical Implications

Abstract

Deprescribing in patients with complex multimorbidity is a critical process aimed at optimizing pharmacotherapy, minimizing polypharmacy-associated risks, and improving clinical outcomes. This review synthesizes current evidence and guideline recommendations, focusing on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, therapeutic management, and recent advances in deprescribing for multimorbid patients. Emphasis is placed on mechanisms underlying drug-related harm, practical implications for clinicians, and emerging therapies. The article provides a comprehensive, evidence-based, and clinically relevant overview for healthcare professionals managing polypharmacy in multimorbid populations.

Introduction

Polypharmacy is prevalent among adults with complex multimorbidity, defined as the coexistence of two or more chronic conditions. The growing aging population and advances in chronic disease management have increased the number of individuals exposed to multiple drugs, raising concerns about adverse drug events (ADEs), drug-drug interactions, and diminished quality of life. Deprescribing—the systematic process of tapering, withdrawing, or discontinuing medicines—has emerged as a pivotal strategy to address these challenges. This review aims to elucidate the evidence base, mechanisms, and practical aspects of deprescribing in complex multimorbidity, providing clinicians with actionable guidance grounded in current guidelines and research.

Epidemiology / Disease Burden

Complex multimorbidity affects a significant proportion of the adult population, particularly the elderly. Studies estimate that nearly 70% of adults over 65 have two or more chronic diseases, with 30–50% prescribed five or more medications concurrently. Polypharmacy is strongly associated with increased hospitalizations, ADEs, medication-related problems, and health care costs. The global burden is further compounded by variations in healthcare systems, prescribing cultures, and access to care, highlighting the need for standardized deprescribing frameworks.

Pathophysiology

The underlying pathophysiology in complex multimorbidity relates to age- and disease-related changes in pharmacokinetics and pharmacodynamics. Altered drug absorption, distribution, metabolism, and excretion—coupled with organ dysfunction—predispose patients to increased drug sensitivity and toxicity. Furthermore, drugs prescribed for one condition can exacerbate or mask the manifestations of another (therapeutic competition), complicating clinical management. The cumulative anticholinergic, sedative, and metabolic burdens of polypharmacy can accelerate frailty, cognitive decline, and functional impairment.

Risk Factors

Key risk factors for inappropriate polypharmacy include advanced age, frailty, cognitive impairment, renal or hepatic dysfunction, frequent transitions of care, and lack of coordinated management among multiple prescribers. Socioeconomic disparities, limited health literacy, and patient or caregiver preferences may further contribute to unnecessary medication use. Certain drug classes—such as benzodiazepines, antipsychotics, and anticholinergics—carry disproportionately high risks in multimorbid patients and warrant particular scrutiny during deprescribing.

Clinical Features

Clinical manifestations of problematic polypharmacy are often non-specific and may include falls, delirium, dizziness, orthostatic hypotension, gastrointestinal disturbances, and unexplained functional decline. Polypharmacy can obscure the clinical picture, making it challenging to attribute symptoms to specific drugs or disease processes. Careful history-taking, medication reconciliation, and assessment of patient goals and preferences are critical in identifying candidates for deprescribing.

Diagnosis

Diagnosing medication-related harm in the context of complex multimorbidity requires a comprehensive, patient-centered approach. Structured tools such as the Medication Appropriateness Index, Beers Criteria, and STOPP/START criteria are invaluable for identifying potentially inappropriate medications (PIMs). Regular medication reviews, particularly following hospitalizations or significant clinical changes, facilitate timely recognition of adverse effects and inform shared decision-making regarding deprescribing.

Treatment & Management

The deprescribing process involves several key steps: comprehensive medication review, identification of PIMs, risk-benefit assessment, shared decision-making, and individualized tapering or cessation. Multidisciplinary collaboration—incorporating pharmacists, physicians, nurses, and patients—is essential for safe and effective deprescribing. Monitoring for withdrawal phenomena, relapse of underlying disease, and new or unmasked symptoms is critical. Communication, education, and follow-up are necessary to address patient concerns and optimize adherence to revised regimens.

Recent Advances / Emerging Therapies

Recent advances include the development of digital deprescribing tools, decision support systems, and risk prediction algorithms to facilitate evidence-based medication optimization. Pragmatic clinical trials and implementation studies have demonstrated the safety and efficacy of pharmacist-led and interprofessional deprescribing interventions in reducing polypharmacy and improving patient-reported outcomes. Ongoing research is exploring biomarker-guided approaches, artificial intelligence-driven drug reconciliation, and patient-tailored deprescribing strategies.

Guideline Recommendations

International guidelines from organizations such as the National Institute for Health and Care Excellence (NICE), American Geriatrics Society, and Canadian Deprescribing Network emphasize routine medication review, prioritization of patient goals, and engagement of patients and caregivers in the deprescribing process. Recommendations highlight the importance of individualized care, use of validated screening tools, and ongoing monitoring. Guidelines underscore the need to balance reduction of medication burden with maintenance of disease control and quality of life.

Conclusion

Deprescribing in complex multimorbidity is a nuanced, evidence-based process integral to optimizing care for patients exposed to polypharmacy. Clinicians must remain vigilant for medication-related risks, employ structured assessment tools, and engage in multidisciplinary collaboration. Adherence to guideline recommendations and ongoing research into innovative deprescribing strategies will continue to enhance clinical outcomes, patient safety, and quality of life in this vulnerable population.